Perseus Proteomics, Inc. (JP:4882) has released an update. Perseus Proteomics, Inc. has announced that the Phase I clinical trial results of their anti-transferrin receptor 1 antibody, PPMX-T003, for ...

Perseus Proteomics, Inc. (JP:4882) has released an update. Perseus Proteomics Inc. has reported non-operating income from outsourcing services and faced foreign exchange losses and other expenses in ...

Perseus Proteomics, Inc. (JP:4882) has released an update. Pick the best stocks and maximize your portfolio: Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily ...

Article ‘Count’ and ‘Share’ for Perseus Proteomics Inc. based on listed parameters only. The articles listed below published by authors from Perseus Proteomics Inc., organized by journal and article, ...

Perseus Proteomics Inc. (4882.TO) Japan Half-Year Ended September 30 PARENT 2025 2024 Revenue Y60.00 mln Y59.00 mln Operating Profit (Y399.00 mln) (Y414.00 mln) Pretax Profit (Y345.00 mln) (Y427.00 ...

Perseus Proteomics Inc. and Ube Corp. have disclosed antibody-drug conjugates (ADCs) comprising antibodies T004b-PGAP-1 targeting human P-cadherin (CDH3) targeting covalently linked to cytotoxic drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

No articles found. Perseus Proteomics Inc. did not contribute to any primary research papers from Nature Index journals in the current 12 month window. The Nature Index 2025 Research Leaders — ...